Explore the latest in myasthenia gravis, including recent advances in diagnosis and management of patients with the disorder.
A man in his 50s with nonalcoholic steatohepatitis and hepatocellular carcinoma undergoing checkpoint inhibitor therapy experiences weakness and myalgia. What is your diagnosis?
This study assesses the response to rituximab in the treatment of patients with refractory acetylcholine receptor autoantibody–positive generalized myasthenia gravis.
This cross-sectional study examines the clinical features of patients with double-seronegative myasthenia gravis who have cortactin antibodies.
This study reports 7 cases of severe myasthenia gravis treated with autologous hematopoietic stem cell transplant in which consistent, durable, symptom-free, and treatment-free remission was achieved.
This cohort study reports a significant association between older age, male sex, and progression to generalized myasthenia gravis and positive acetylcholine receptor antibody test results in patients with ocular myasthenia gravis.
This study characterized the clinical, structural, electrophysiologic, and genetic features of a congenital myasthenic syndrome, identified the disease gene and mutation, confirmed pathogenicity of the mutation by expression studies, and instituted optimal pharmacotherapy.
This Special Communication reports on the latest research in myasthenia, which results from dysfunction of the neuromuscular synapse (ie, the neuromuscular junction), causing clinical “fatigue” that is defined as muscle weakness that worsens with muscle use and improves with rest.
This cohort study determines the diagnostic usefulness of cell-based assays in the diagnosis of myasthenia gravis and compares the clinical features of patients with antibodies only to clustered acetylcholine receptors with those of patients with seronegative myasthenia gravis. See the Editorial by Vernino.
This genome-wide association study provides insights into aberrant cellular mechanisms responsible for myasthenia gravis.
Liew and colleagues aimed to determine whether plasmapheresis or intravenous immunoglobulin (IVIG) therapy is more effective as maintenance therapy in juvenile myasthenia gravis.
Fleisher and coauthors report of a single case of a 53-year-old man with myasthenia gravis and a prior thymectomy presenting with 2 months of diffuse, involuntary muscle twitching in the absence of myasthenic symptoms, electrophysiologically confirmed to be neuromyotonia. Further evaluation revealed the recurrence of malignant thymoma, accompanied by refractory arrhythmia.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: